Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab

Mirabegron plus solifenacin shows promise in overactive bladder treatment

Jairia Dela Cruz
13 Sep 2018

A 12-month treatment course with the combination of mirabegron plus solifenacin is safe and effective in patients with overactive bladder (OAB), reducing the number of incontinence episodes and micturition without unexpected toxicities, according to the results of the phase III SYNERGY II study.

“These favourable long-term data showcase the potential of [the said] novel combination treatment option for patients with OAB,” who require long-term treatment to achieve adequate symptom control, the investigators said.

The analysis included 1,794 patients (median age 60 years; 80 percent female) with “wet” OAB symptoms (urinary frequency and urgency with incontinence) for ≥3 months. Following a 2-week placebo run-in, these patients were randomized to 12-month treatment with solifenacin succinate 5 mg plus mirabegron 50 mg (combination; n=1,193), solifenacin 5 mg alone (n=299), or mirabegron 50 mg alone (n=302).

The combination therapy yielded superior reductions in the number of incontinence episodes compared with mirabegron monotherapy (adjusted mean difference [AMD], −0.5; 95 percent CI, −0.7 to −0.2; p<0.001) and solifenacin monotherapy (AMD, −0.1; −0.4 to 0.1; p=0.002). [Eur Urol 2018;doi:10.1016/j.eururo.2018.05.005]

Likewise, improvements in micturition were better with the combination therapy vs mirabegron alone (AMD, −0.5; −0.8 to −0.2; p<0.001) and solifenacin alone (AMD, −0.4; −0.7 to −0.1; p=0.004).

A total of 856 patients (47 percent) had ≥1 treatment-emergent adverse events (TEAEs), the primary safety outcome. TEAEs occurred with slightly greater frequency in the combination group vs the solifenacin and mirabegron monotherapy groups (49 percent vs 41 percent vs 44 percent, respectively), with dry mouth being the most common event.

Serious TEAEs were reported in 67 patients (3.7 percent), with one case of atrial fibrillation in the mirabegron group considered to be potentially related to treatment.

The present data confirm and extend the results of the 12-week phase III SYNERGY study, which has shown clinically relevant improvements in incontinence episodes and micturition after short-term treatment with solifenacin 5 mg in combination with mirabegron 25 or 50 mg as compared with the individual monotherapies in the general OAB population with urinary incontinence. [BJU Int 2017;120:562-575]

“Mirabegron and solifenacin have different mechanisms of action, and coadministration appears to have no noticeable effect on their pharmacokinetics,” the investigators noted.

Indeed, findings from the present and previous studies have demonstrated that combination treatment for 12 weeks up to 1 year improves OAB outcomes without a substantial impact on the safety profile when compared with monotherapies. [J Urol 2016;196:809-818; Eur Urol 2016;70:136-145]

The study has several limitations, including the fact that most of the patients enrolled had completed the previous studies evaluating the efficacy and safety of short-term solifenacin–mirabegron treatment for OAB.

As a result, the population may have been skewed towards those who had experienced a favourable response and/or positive safety outcome following combination treatment or monotherapy, the investigators pointed out.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 01 Oct 2019

The European Society of Cardiology (ESC) has released five new guidelines at the ESC Congress 2019, recommending an even lower LDL-C* target in patients at very high risk for cardiovascular disease (CVD), and the use of SGLT2** inhibitors and GLP-1*** receptor agonists as first-line treatments in those with diabetes to reduce their CVD risk.

Roshini Claire Anthony, 16 Dec 2016

Five years of extended therapy with the aromatase inhibitor (AI) letrozole did not improve survival in postmenopausal breast cancer patients, according to findings of the NRG Oncology/NSABP B-42 trial presented at the San Antonio Breast Cancer Symposium (SABCS 2016) held in Texas, US. 

Jackey Suen, 21 Dec 2016

Adding everolimus to fulvestrant in second-line treatment of hormone receptor (HR)-positive, HER2-negative advanced breast cancer improves progression-free survival (PFS) by 40 percent, the phase II PrECOG 0102 study has shown. [SABCS 2016, abstract S1-02]

29 Nov 2019
Saxagliptin 5 mg, dapagliflozin 10 mg FC tab